What is Graphite Bio Debt-to-Equity?
Graphite Bio's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.29 Mil. Graphite Bio's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.08 Mil. Graphite Bio's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $183.58 Mil.
Graphite Bio's debt to equity for the quarter that ended in Dec. 2023 was 0.00.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Graphite Bio's Debt-to-Equity or its related term are showing as below:
During the past 5 years, the highest Debt-to-Equity Ratio of Graphite Bio was 0.03. The lowest was -0.99. And the median was 0.01.
Graphite Bio Debt-to-Equity Historical Data
The historical data trend for Graphite Bio's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Graphite Bio Debt-to-Equity Chart
|
Graphite Bio Annual Data
|
|
Trend |
Dec19 |
Dec20 |
Dec21 |
Dec22 |
Dec23 |
| Debt-to-Equity |
|
-0.99 |
- |
0.03 |
0.02 |
- |
|
Graphite Bio Quarterly Data
|
|
Dec19 |
Mar20 |
Jun20 |
Sep20 |
Dec20 |
Mar21 |
Jun21 |
Sep21 |
Dec21 |
Mar22 |
Jun22 |
Sep22 |
Dec22 |
Mar23 |
Jun23 |
Sep23 |
Dec23 |
| Debt-to-Equity |
Get a 7-Day Free Trial
|
|
|
|
|
|
|
|
|
|
0.02 |
0.02 |
0.24 |
0.26 |
- |
Competitive Comparison of Graphite Bio's Debt-to-Equity
For the Biotechnology subindustry, Graphite Bio's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Graphite Bio's Debt-to-Equity Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Graphite Bio's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Graphite Bio's Debt-to-Equity falls into.
Graphite Bio Debt-to-Equity Calculation
Debt to Equity measures the financial leverage a company has.
Graphite Bio's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as
Graphite Bio's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Graphite Bio (Graphite Bio) Business Description
Traded in Other Exchanges
N/A
Address
201 Haskins Way, Suite 210, South San Francisco, CA, USA, 94080
Graphite Bio Inc is a clinical-stage gene-editing company harnessing gene integration to develop a new class of therapies to cure serious and life-threatening diseases. Its gene-editing platform allows to precisely correct mutations, replace entire disease-causing genes with normal genes, or insert new genes into predetermined, safe locations. Its product candidate GPH101 is a differentiated approach with the potential to directly correct the mutation that causes sickle cell disease (SCD) and restore normal adult hemoglobin (HgbA) expression. All of the company's long-lived assets are based in the United States.
Executives
| Kimberlee C Drapkin |
director |
PREDIX PHARMACEUTICALS HOLDINGS, INC., 4 MAGUIRE ROAD, LEXINGTON MA 02421 |
| Ecor1 Capital, Llc |
10 percent owner |
357 TEHAMA STREET #3, SAN FRANCISCO CA 94103 |
| Samsara Biocapital, L.p. |
10 percent owner |
628 MIDDLEFIELD ROAD, PALO ALTO CA 94301 |
| Phil Gutry |
officer: CHIEF BUSINESS OFFICER |
400 E. PRATT STREET, SUITE 606, BALTIMORE MD 21202 |
| Alethia Young |
officer: Chief Financial Officer |
C/O GRAPHITE BIO, INC., 201 HASKINS WAY, SUITE 210, SOUTH SAN FRANCISCO CA 94080 |
| Versant Ventures Vi Gp, L.p. |
10 percent owner |
ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104 |
| Matthew Porteus |
director |
C/O GRAPHITE BIO, INC., 279 EAST GRAND AVENUE, SUITE 430, SOUTH SAN FRANCISCO CA 94080 |
| Katherine V Stultz |
officer: CHIEF OPERATING OFFICER |
C/O GRAPHITE BIO, INC., 279 EAST GRAND AVENUE, SUITE 430, SOUTH SAN FRANCISCO CA 94080 |
| Abraham Bassan |
director |
C/O GRAPHITE BIO, INC., 279 EAST GRAND AVENUE, SUITE 430, SOUTH SAN FRANCISCO CA 94080 |
| L.p. 436, |
10 percent owner |
628 MIDDLEFIELD ROAD, PALO ALTO CA 94301 |
| Versant Vantage Ii Gp, L.p. |
10 percent owner |
ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104 |
| Versant Vantage Ii Gp-gp, Llc |
10 percent owner |
ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104 |
| Versant Vantage Ii, L.p. |
10 percent owner |
ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104 |
| Rizzuto Carlo |
director |
ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104 |
| Smital Shah |
director |
C/O PLIANT THERAPEUTICS, INC., 260 LITTLEFIELD AVENUE, SOUTH SAN FRANCISCO CA 94080 |
Graphite Bio (Graphite Bio) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
GRPH has been successfully added to your